New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2014
07:59 EDTROSGRosetta Genomics platform predicts bladder cancer progression in published study
Rosetta Genomics announces the publication of clinical data in an article entitled, "The role of microRNA profiling in prognosticating progression in Ta and T1 urinary bladder cancer." The study profiled and analyzed microRNA expression levels in 86 samples of non-muscle-invasive bladder cancer to identify patterns of expression that are indicative of a high probability of disease progression. The main finding showed that in the least invasive tumors, low expression levels of miR-10a are correlated to later recurrence of the disease in a more invasive form. According to study author, Ulrika Segersten, Ph.D., Department of Surgical Sciences, Uppsala University, Uppsala, Sweden, "Profiling revealed that certain microRNAs predicted the risk of developing higher stage among patients with Ta cancers. Lower miR-10a-5p expression in Ta progressing tumors indicates that this microRNA could have a crucial role for later invasion of non-invasive bladder tumors."
News For ROSG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
08:28 EDTROSGRosetta Genomics announces results for microRNA thyroid assay
Subscribe for More Information
February 18, 2015
09:33 EDTROSGRosetta Genomics enters $14.4M controlled equity offering sales agreement
Subscribe for More Information
February 17, 2015
08:19 EDTROSGRosetta Genomics announces U.S., European patent allowances for microRNA
Rosetta Genomics announced that the company received a Notice of Allowance from the United States Patent and Trademark Office for a patent claiming the use of miR-34a for the treatment of p53-associated cancers. In addition, the company announced its first allowance from the European Patent Office for a patent claiming the specific composition for miR-451, a miR relating to the company’s Cancer of Unknown Primary testing franchise. The allowed claims for the U.S. patent cover a core element of Rosetta Genomics’ microRNA technology in the development of cancer therapeutics relating to cancers associated with the p53 gene. This patent is broader than the previous patent issued last year in that it covers the treatment of any p-53 associated cancer using miR-34a or its variants, delivered by any kind of formulation. The patent is jointly owned with Yeda Research and Development. The allowed claims for the European patent cover miR-451 and its complement, as well as a probe comprising the claimed miR. Therapeutic and diagnostic uses of the miR and/or the probe are also covered in the allowed claims.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use